In addition, the clinic team helps patients navigate care and their insurance authorization process, reducing one of the biggest headaches for patients. Team members also provide help with copays and finances, as necessary.
“The Clinic allows patients to maintain their quality of life, receive excellent care with fewer visits, and avoid liver biopsies with on-site FibroScans,” says Parodi. “The clinic staff is a comprehensive team of experts who stay updated on evolving treatments. This team is dedicated full time to hepatitis C patients.”
At TPMG 12,000 patients have been treated since 2011 with DAA within a broader scope of treatment and based on a personalized treatment plan designed between the physician and their patient Within this population an estimated 2,300 patients avoided cirrhosis, 500 avoided a liver transplant, and 250 avoided eventual death.
“Healthcare executives should be interested because of the significant cost associated with the hepatitis C medications themselves as well as the case management needed to ensure adherence and virologic success with this potentially curative therapy,” he says. “The upfront investment in a comprehensive case management system for hepatitis C will increase the chances of cure and reduce the long-term consequences related to hep C which includes the risk for developing end stage liver disease related to cirrhosis and hepatocellular cancer. Those overall aims help the individual patient and the health system at large.”
He adds there are other disease states that will be addressed by the taskforce in the future due to their regular assessments on evidence for preventive services and grading the evidence of benefits and harms. Often outside organizations, such as professional societies or associations, nominate services for the Task Force to review.
Briana Contreras is associate editor of Managed Healthcare Executive.